Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04504526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

StatusRecruiting
PhaseEarly Phase 1
Started2020-08-07
View on ClinicalTrials.gov ↗

Amendment history

2026-07-19
Study Status v4
Primary completion date2024-12→2027-12
Completion date2024-12→2027-12-31
2023-09-14
Study Status v3
Primary completion date2023-08→2024-12
Completion date2023-12→2024-12
2023-02-15
Study Status v2
Re-verified, no change to tracked fields
2021-04-06
Study Status v1
Start dateestimated 2020-08→confirmed 2020-08-07
2020-08-06
Original filing
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.
Trial Details
NCT Number NCT04504526
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Lymphoma, Multiple Myeloma, Leukemia
Enrollment 50 participants
Start Date 2020-08-07
Primary Completion 2027-12 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21